ClinicalTrials.gg
Active, not recruitingNCT07884734Updated Oct 21, 2026

A Study to Evaluate the Effect of Carbamazepine or Itraconazole on Radiprodil in Healthy Adult Participants

A Phase 1 interventional study of Radiprodil and Carbamazepine in Healthy Adult Participants, sponsored by GRIN Therapeutics, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by GRIN Therapeutics, Inc. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jun 2026, registered Oct 2026).
Updated Oct 21, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1, open-label, 2-part study in healthy adult participants to evaluate the pharmacokinetics and safety of radiprodil when coadministered with either the CYP3A4 inducer carbamazepine or the CYP3A4 inhibitor itraconazole. Up to 36 participants will be enrolled, with approximately 18 participants in Part A and 18 participants in Part B.

Read the detailed description

Part A will evaluate the effect of carbamazepine on the plasma pharmacokinetic profile of radiprodil. Participants will receive a single 30 mg oral dose of radiprodil under fed conditions, followed by multiple oral doses of carbamazepine, and then coadministration of radiprodil 30 mg with carbamazepine 300 mg.

Part B will evaluate the effect of itraconazole on the plasma pharmacokinetic profile of radiprodil. Participants will receive a single 15 mg oral dose of radiprodil under fed conditions, followed by multiple oral doses of itraconazole, and then coadministration of radiprodil 15 mg with itraconazole 200 mg.

02

Conditions studied

  • Healthy Adult Participants

Keywords

  • Radiprodil
  • Carbamazepine
  • Itraconazole
03

In context

Lead sponsor

GRIN Therapeutics, Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female adults aged 18 to 55 years inclusive at Screening.
  • between 18 and 32 kg/m² inclusive and weight of at least 50 kg at Screening.
  • Healthy in the opinion of the Principal Investigator, based on medical history, physical examination, 12-lead , vital signs, and clinical laboratory assessments.
  • Female participants must be non-lactating and either of non-, , or, if of childbearing potential, must have negative pregnancy tests and agree to required and ova donation restrictions.
  • Male participants must agree to sperm donation restrictions and required contraception measures.
  • For Part A only, participants must not be of Asian descent due to increased risk associated with carbamazepine exposure.
  • Able to provide signed and comply with study requirements, including dietary restrictions and confinement at the clinical research unit.

Exclusion criteria

Exclusion Criteria:

  • History of or to radiprodil, carbamazepine, itraconazole, or formulation components.
  • For Part A only, HLA genotypes associated with increased risk of carbamazepine-induced severe cutaneous adverse reactions.
  • Any medical condition that, in the opinion of the Principal Investigator, would pose additional risk or interfere with drug absorption, distribution, metabolism, or excretion.
  • Pregnancy, breastfeeding, or positive pregnancy test.
  • Significant neuropsychiatric, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, urologic, neurological, , psychiatric disease, brain surgery, or brain injury.
  • allergic conditions.
  • History of illicit drug abuse or alcohol abuse within 2 years of Screening.
  • History of suicide attempt, deliberate self-harm, significant suicidal ideation, or suicidal behaviour on C-SSRS.
  • Excessive alcohol or caffeine consumption.
  • Positive drug, alcohol, cotinine, or relevant substance screen at Screening or Day -1.
  • Recent marijuana, tobacco, nicotine, prescription drug, product, OTC medication, herbal product, vaccine, blood donation, acute illness, relevant surgery, or blood transfusion as defined in the protocol.
  • Positive serology for , antibody, or antibody.
  • Abnormal blood pressure, pulse rate, clinically significant abnormality, >450 msec, or history of prolonged QT syndrome.
  • Restricted food or drink consumption before dosing, including alcohol, grapefruit/pomelo/star fruit/Seville orange products, poppy seeds, and xanthine-containing products.
  • Poor venous access.
  • Women of using oral, injected, or implanted hormonal .
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Part A: Radiprodil With Carbamazepine

    Participants will receive a single oral dose of radiprodil 30 mg under fed conditions on Day 1. Carbamazepine will then be administered orally twice daily with food at escalating doses: 100 mg BID on Days 4 to 5, 200 mg BID on Days 6 to 7, and 300 mg BID on Days 8 to 15. On Day 16, radiprodil 30 mg will be coadministered with carbamazepine 300 mg under fed conditions. Carbamazepine 300 mg BID will continue on Days 17 to 18. Participants will be discharged on Day 21 and attend a follow-up visit 30 days ± 2 days after the last carbamazepine dose.

    Drug: Radiprodil · Drug: Carbamazepine

  • Experimental
    Part B: Radiprodil With Itraconazole

    Participants will receive a single oral dose of radiprodil 15 mg under fed conditions on Day 1. Itraconazole 200 mg once daily will be administered orally with food on Days 4 to 8. On Day 9, radiprodil 15 mg will be coadministered with itraconazole 200 mg under fed conditions. Itraconazole 200 mg once daily will continue on Days 10 to 11. Participants will be discharged on Day 12 and attend a follow-up visit 30 days ± 2 days after the last itraconazole dose.

    Drug: Radiprodil · Drug: Itraconazole (200 mg)

Interventions

  • Radiprodil administered orally as a single dose of 30 mg in Part A or 15 mg in Part B under fed conditions.

    Also known as: RGH-896, Radiprodil oral suspension

  • Carbamazepine administered orally twice daily at doses of 100 mg, 200 mg, and 300 mg in Part A to evaluate the effect of CYP3A4 induction on the pharmacokinetics of radiprodil.

  • Itraconazole administered orally at 200 mg once daily in Part B to evaluate the effect of CYP3A4 inhibition on the pharmacokinetics of radiprodil.

06

What researchers measure

Primary outcomes

  1. AUClast of Radiprodil - Part A

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUClast) of radiprodil following administration of radiprodil alone on Day 1 and with carbamazepine on Day 16. The effect of carbamazepine will be assessed using the geometric mean ratio and 90% confidence interval.

    Time frame: Part A: Day 1 through Day 19

  2. AUCinf of Radiprodil - Part A

    Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf) of radiprodil following administration of radiprodil alone on Day 1 and with carbamazepine on Day 16. The effect of carbamazepine will be assessed using the geometric mean ratio and 90% confidence interval.

    Time frame: Part A: Day 1 through Day 19

  3. Cmax of Radiprodil - Part A

    Maximum observed plasma concentration (Cmax) of radiprodil following administration of radiprodil alone on Day 1 and with carbamazepine on Day 16. The effect of carbamazepine will be assessed using the geometric mean ratio and 90% confidence interval.

    Time frame: Part A: Day 1 through Day 19

  4. AUClast of Radiprodil - Part B

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration (AUClast) of radiprodil following administration of radiprodil alone on Day 1 and with itraconazole on Day 9. The effect of itraconazole will be assessed using the geometric mean ratio and 90% confidence interval.

    Time frame: Part B: Day 1 through Day 12

  5. AUCinf of Radiprodil - Part B

    Area under the plasma concentration-time curve from time zero extrapolated to infinity (AUCinf) of radiprodil following administration of radiprodil alone on Day 1 and with itraconazole on Day 9. The effect of itraconazole will be assessed using the geometric mean ratio and 90% confidence interval.

    Time frame: Part B: Day 1 through Day 12

  6. Cmax of Radiprodil - Part B

    Maximum observed plasma concentration (Cmax) of radiprodil following administration of radiprodil alone on Day 1 and with itraconazole on Day 9. The effect of itraconazole will be assessed using the geometric mean ratio and 90% confidence interval.

    Time frame: Part B: Day 1 through Day 12

Secondary outcomes

  1. AUClast of Carbamazepine - Part A

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration of carbamazepine following administration alone and in combination with radiprodil.

    Time frame: Part A: Day 16 (up to 12 hours post-dose)

  2. AUCtau of Carbamazepine - Part A

    Area under the plasma concentration-time curve over the 12-hour dosing interval (AUCtau) of carbamazepine following coadministration with radiprodil.

    Time frame: Part A: Day 16 (up to 12 hours post-dose)

  3. Cmax of Carbamazepine - Part A

    Maximum observed plasma concentration (Cmax) of carbamazepine following coadministration with radiprodil.

    Time frame: Part A: Day 16 (up to 12 hours post-dose)

  4. Tmax of Carbamazepine - Part A

    Time to reach maximum observed plasma concentration of carbamazepine following administration alone and in combination with radiprodil.

    Time frame: Part A: Day 16 (up to 12 hours post-dose)

  5. AUClast of Itraconazole - Part B

    Area under the plasma concentration-time curve from time zero to the last quantifiable concentration of itraconazole following administration alone and in combination with radiprodil.

    Time frame: Part B: Day 9 through Day 10 (up to 24 hours post-dose)

  6. AUCtau of Itraconazole - Part B

    Area under the plasma concentration-time curve over the dosing interval of itraconazole following administration alone and in combination with radiprodil.

    Time frame: Part B: Day 9 through Day 10 (up to 24 hours post-dose)

  7. Cmax of Itraconazole - Part B

    Maximum observed plasma concentration of itraconazole following administration alone and in combination with radiprodil.

    Time frame: Part B: Day 9 through Day 10 (up to 24 hours post-dose)

  8. Tmax of Itraconazole - Part B

    Time to reach maximum observed plasma concentration of itraconazole following administration alone and in combination with radiprodil.

    Time frame: Part B: Day 9 through Day 10 (up to 24 hours post-dose)

  9. Tmax of Radiprodil - Part A

    Time to reach maximum observed plasma concentration of radiprodil. Assessed following administration of radiprodil alone and in combination with carbamazepine.

    Time frame: Part A: Day 1 through Day 19

  10. Terminal Elimination Half-Life (t½) of Radiprodil - Part A

    Terminal elimination half-life of radiprodil, defined as the time required for plasma concentration to decrease by half during the terminal elimination phase. Assessed following administration of radiprodil alone and in combination with carbamazepine.

    Time frame: Part A: Day 1 through Day 19

  11. Apparent Total Body Clearance (CL/F) of Radiprodil - Part A

    Apparent total body clearance of radiprodil following oral administration. Assessed following administration of radiprodil alone and in combination with carbamazepine.

    Time frame: Part A: Day 1 through Day 19

  12. Apparent Volume of Distribution (Vz/F) of Radiprodil - Part A

    Apparent volume of distribution of radiprodil during the terminal elimination phase following oral administration. Assessed following administration of radiprodil alone and in combination with carbamazepine.

    Time frame: Part A: Day 1 through Day 19

  13. Tmax of Radiprodil - Part B

    Time to reach maximum observed plasma concentration of radiprodil. Assessed following administration of radiprodil alone and in combination with itraconazole.

    Time frame: Part B: Day 1 through Day 12

  14. Terminal Elimination Half-Life (t½) of Radiprodil - Part B

    Terminal elimination half-life of radiprodil, defined as the time required for plasma concentration to decrease by half during the terminal elimination phase. Assessed following administration of radiprodil alone and in combination with itraconazole.

    Time frame: Part B: Day 1 through Day 12

  15. Apparent Total Body Clearance (CL/F) of Radiprodil - Part B

    Apparent total body clearance of radiprodil following oral administration. Assessed following administration of radiprodil alone and in combination with itraconazole.

    Time frame: Part B: Day 1 through Day 12

  16. Apparent Volume of Distribution (Vz/F) of Radiprodil - Part B

    Apparent volume of distribution of radiprodil during the terminal elimination phase following oral administration. Assessed following administration of radiprodil alone and in combination with itraconazole.

    Time frame: Part B: Day 1 through Day 12

  17. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Number and percentage of participants with at least one treatment-emergent adverse event (TEAE), summarised by treatment period and overall for each study part. TEAEs are adverse events occurring or worsening after the first dose of study drug.

    Time frame: From first dose of study drug through follow-up (up to approximately 90 days in Part A and 69 days in Part B)

  18. Number of Participants With Serious Adverse Events (SAEs)

    Number of participants experiencing at least one serious adverse event, summarised separately for each study part.

    Time frame: From signing of informed consent through follow-up (up to approximately 90 days in Part A and 69 days in Part B)

  19. Change From Baseline in Systolic Blood Pressure

    Change from baseline in systolic blood pressure, measured in mmHg, summarised by scheduled assessment time point and treatment period within each study part.

    Time frame: From baseline through follow-up

  20. Change From Baseline in Diastolic Blood Pressure

    Change from baseline in diastolic blood pressure, measured in mmHg, summarised by scheduled assessment time point and treatment period within each study part.

    Time frame: From baseline through follow-up

  21. Change From Baseline in Pulse Rate

    Change from baseline in pulse rate, measured in beats per minute, summarised by scheduled assessment time point and treatment period within each study part.

    Time frame: From baseline through follow-up

  22. Change From Baseline in Body Temperature

    Change from baseline in body temperature, measured in degrees Celsius, summarised by scheduled assessment time point and treatment period within each study part.

    Time frame: From baseline through follow-up

  23. Change From Baseline in Respiratory Rate

    Change from baseline in respiratory rate, measured in breaths per minute, summarised by scheduled assessment time point and treatment period within each study part.

    Time frame: From baseline through follow-up

  24. Number of Participants With QTcF Interval Above 450 Milliseconds

    Number of participants with a QT interval corrected using Fridericia's formula (QTcF) greater than 450 milliseconds during the study.

    Time frame: From baseline through follow-up

  25. Number of Participants With QTcF Interval Above 480 Milliseconds

    Number of participants with a QTcF interval greater than 480 milliseconds during the study.

    Time frame: From baseline through follow-up

  26. Number of Participants With QTcF Interval Above 500 Milliseconds

    Number of participants with a QTcF interval greater than 500 milliseconds during the study.

    Time frame: From baseline through follow-up

  27. Number of Participants With QTcF Increase From Baseline of at Least 30 Milliseconds

    Number of participants with an increase in QTcF from baseline of at least 30 milliseconds during the study.

    Time frame: From baseline through follow-up

  28. Number of Participants With QTcF Increase From Baseline of at Least 60 Milliseconds

    Number of participants with an increase in QTcF from baseline of at least 60 milliseconds during the study.

    Time frame: From baseline through follow-up

07

Study locations

1 site
  • California Clinical Trials Medical Group (CCTMG)
    Glendale, California 91206, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Oct 2026, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2026
First posted
Oct 21, 2026
StartActual
Jun 8, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Oct 31, 2026
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07884734
Lead sponsor
GRIN Therapeutics, Inc.
Collaborators
Parexel
Responsible party
Sponsor
First posted
Oct 21, 2026
Start date
Jun 8, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Oct 31, 2026 (estimated)
Last update
Oct 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carbamazepine · Itraconazole

Start the discussion